Comparative study of inhibitory antibody derivatives towards thrombin activatable fibrinolysis inhibitor

Summary

Thrombin activatable fibrinolysis inhibitor (TAFI) attenuates fibrinolysis and is considered as an attractive drug target. We generated two different antibody fragments, an antigen-binding fragment (Fab) and a single-chain variable fragment (scFv), derived from three distinct monoclonal antibodies (MAs) that inhibit the activation of TAFI by the thrombin/thrombomodulin complex (T/TM) and plasmin (MA-T1C10 and MA-T94H3) or by T/TM alone (MA-T12D11). The Fabs were obtained by papain digestion of the purified Mas, whereas the scFvs were cloned and subsequently expressed in bacteria. All antibody fragments revealed similar or slightly decreased affinities compared to those of the respective Mas, except scFv-T94H3. In the presence of a 16-fold molar excess of all antibody fragments, activation of TAFI by T/TM was completely blocked. Furthermore, Fab and scFv-derivatives from MA-T1C10 and MA-T94H3 were capable of interfering with the plasmin-mediated activation of TAFI. Addition of 850 nM of MA, Fab or scFv to an in-vitro clot lysis assay caused a significant reduction of clot lysis time (except for scFv-T94H3) and this effect was comparable to that of potato tuber carboxypeptidase inhibitor, a well-known TAFIa inhibitor. Dose-response experiments with the antibody (derivatives) in clot lysis and chromogenic assay revealed that the inhibitory capacity of the Fabs was comparable to that of the Mas, whereas the scFvs had a more reduced potency. In conclusion, these highly specific TAFI inhibitors are interesting tools to further evaluate the concept of TAFI inhibition in various in-vitro and in-vivo models.

Keywords

Thrombin activatable fibrinolysis inhibitor (TAFI) / carboxypeptidases - drug design - fibrinolysis - antibody - single-chain Fv

• References

• 1 Fleury V, Angles-Cano E. Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. Biochemistry 1991; 30: 7630-7638.
• 2 Wang W, Boffa MB, Bajzar L. et al. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-27181.
• 3 te Velde EA, Wagenaar GTM, Reijerkerk A. et al. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2003; 01: 2087-2096.
• 4 Myles T, Nishimura T, Yun TH. et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003; 278: 51059-51067.
• 5 Asai S, Sato T, Tada T. et al. Absence of procarboxypeptidase R induces complement-mediated lethal inflammation in lipopolysaccharide-primed mice. J Immunol 2004; 173: 4669-4674.
• 6 Boffa MB, Koschinsky ML. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem 2007; 40: 431-442.
• 7 Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-16608.
• 8 Boffa MB, Wang W, Bajzar L. et al. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J Biol Chem 1998; 273: 2127-2135.
• 9 Boffa MB, Bell R, Stevens WK. et al. Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 2000; 275: 12868-12878.
• 10 Marx PF, Hackeng TM, Dawson PE. et al. Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage. J Biol Chem 2000; 275: 12410-12415.
• 11 Silveira A, Schatteman K, Goossens F. et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost 2000; 84: 364-368.
• 12 van-Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-2859.
• 13 Redlitz A, Nicolini FA, Malycky JL. et al. Inducible carboxypeptidase activity. A role in clot lysis in vivo. Circulation 1996; 93: 1328-1330.
• 14 Minnema MC, Friederich PW, Levi M. et al. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest 1998; 101: 10-14.
• 15 Klement P, Liao P, Bajzar L. A novel approach to arterial thrombolysis. Blood 1999; 94: 2735-2743.
• 16 Nagashima M, Werner M, Wang M. et al. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activatorinduced thrombolysis in a rabbit jugular vein thrombolysis model. Thromb Res 2000; 98: 333-342.
• 17 Wang YX, da Cunha V, Vincelette J. et al. A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) – part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis. Thromb Haemost 2007; 97: 54-61.
• 18 Leurs J, Hendriks D. Carboxypeptidase U (TAFIa): a metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease. Thromb Haemost 2005; 94: 471-487.
• 19 Vendrell J, Querol E, Aviles FX. Metallocarboxypeptidases and their protein inhibitors. Structure, function and biomedical properties. Biochim Biophys Acta 2000; 1477: 284-298.
• 20 Gils A, Ceresa E, Macovei AM. et al. Modulation of TAFI function through different pathways-implications for the development of TAFI inhibitors. J Thromb Haemost 2005; 03: 2745-2753.
• 21 Lonberg N. Human antibodies from transgenic animals. Nat Biotechnol 2005; 23: 1117-1125.
• 22 Gils A, Alessi MC, Brouwers E. et al. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003; 23: 1122-1127.
• 23 Develter J, Booth NA, Declerck PJ. et al. Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 by a heterodimer diabody. J Thromb Haemost 2008; 06: 1884-1891.
• 24 Mosnier LO, von-dem-Borne PA, Meijers JC. et al. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-835.
• 25 Mutch NJ, Thomas L, Moore NR. et al. TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots. J Thromb Haemost 2007; 05: 812-817.
• 26 Kipriyanov SM, Moldenhauer G, Martin AC. et al. Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. Protein Eng 1997; 10: 445-453.
• 27 Polla MO, Tottie L, Norden C. et al. Design and synthesis of potent, orally active, inhibitors of carboxypeptidase U (TAFIa). Bioorg Med Chem 2004; 12: 1151-1175.
• 28 Wang YX, Zhao L, Nagashima M. et al. A novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) – part I: pharmacological characterization. Thromb Haemost 2007; 97: 45-53.
• 29 Reichert JM, Rosensweig CJ, Faden LB. et al. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23: 1073-1078.
• 30 Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84: 548-558.
• 31 Hagemeyer CE, Schwarz M, Peter K. Single-chain antibodies as new antithrombotic drugs. Semin Thromb Hemost 2007; 33: 185-195.
• 32 Hagemeyer CE, Tomic I, Jaminet P. et al. Fibrin-targeted direct factor Xa inhibition: construction and characterization of a recombinant factor Xa inhibitor composed of an anti-fibrin single-chain antibody and tick anticoagulant peptide. Thromb Haemost 2004; 92: 47-53.
• 33 Schwarz M, Meade G, Stoll P. et al. Conformationspecific blockade of the integrin GPIIb/IIIa: a novel antiplatelet strategy that selectively targets activated platelets. Circ Res 2006; 99: 25-33.
• 34 Binette TM, Taylor Jr. FB, Peer G. et al. Thrombinthrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon. Blood 2007; 110: 3168-3175.
• 35 Honegger A, Pluckthun A. The influence of the buried glutamine or glutamate residue in position 6 on the structure of immunoglobulin variable domains. J Mol Biol 2001; 309: 687-699.
• 36 Bothmann H, Pluckthun A. Selection for a periplasmic factor improving phage display and functional periplasmic expression. Nat Biotechnol 1998; 16: 376-380.
• 37 Fairlie DP, West ML, Wong AK. Towards protein surface mimetics. Curr Med Chem 1998; 05: 29-62.
• 38 Eichler J. Rational and random strategies for the mimicry of discontinuous protein binding sites. Protein Pept Lett 2004; 11: 281-290.